Genitourinary (Nonprostate) Cancer

ASCO SIGN IN

Username:

Create an account

Why Be A Member?

Password:

Remember me

Forgot your username or password?

The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

ASCO Home

MultiMedia

Virtual Meeting

2005 ASCO Annual Meeting

Genitourinary (Nonprostate) Cancer

Oral Presentation
Chair(s): Daniel J. George, MD; Joaquim Bellmunt, MD
Genitourinary Cancer Track
2005 ASCO Annual Meeting

PRESENTATON TITLE	SPEAKER/ROLE	Basic Player	Enhanced Player
Genitourinary (Nonprostate) Cancer	Joaquim Bellmunt, MD Co-Chair
Genitourinary (Nonprostate) Cancer	Daniel J. George, MD Co-Chair
Sequential dose-intensive paclitaxel plus ifosfamide and carboplatin plus etoposide with autologous stem cell transplantation for germ cell tumor (GCT) patients (pts) Abstract No: 4503	Gnanamba V Kondagunta, MD Presenter
18F]-FDG-PET IN CLINICAL STAGE I AND II NON-SEMINOMATOUS GERM CELL TUMORS: FIRST RESULTS OF THE GERMAN MULTICENTER TRIAL Abstract No: 4504	Maike de Wit, MD Presenter
Discussion	Guy C. Toner, MD, MBBS Discussant
A randomised trial of radical radiotherapy in pT1G3 NXM0 bladder cancer (MRC BS06). Abstract No: 4505	S J Harland, MD Presenter
Muscle-invading bladder cancer, RTOG Protocol 99-06: Initial report of a phase I/II trial of selective bladder-conservation employing TURBT, accelerated irrdiation sensitized with cisplatin and paclitaxel followed by adjuvant cisplatin and gemcitabine chemotherapy. Abstract No: 4506	Donald S Kaufman, MD Presenter
Trastuzumab (T), Paclitaxel (P), Carboplatin (C), and Gemcitabine (G) in Advanced HER2-positive Urothelial Carcinoma: Results of a Multi-Center Phase II NCI Trial Abstract No: 4507	Maha Hussain, MD Presenter
Discussion	Cora N. Sternberg, MD, FACP Discussant
Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC) Abstract No: 4508	Robert J. Motzer, MD Presenter
AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC) Abstract No: 4509	Brian Rini, MD Presenter
Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) Abstract No: 4510	Bernard Escudier, MD Presenter
Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. Abstract No: 4511	Sylvie Negrier, MD, PhD Presenter
Discussion	Michael B. Atkins, MD Discussant

Help

This online resource is supported by:

Primary Supporter